Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?

Bausch + Lomb BLCO shares ended the last trading session 13.9% higher at $12.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 29.2% loss over the past four weeks.

Bausch + Lomb stock surged amid a broader market rebound following the Trump administration’s announcement of a temporary halt on reciprocal tariffs for most countries. The market is also upbeat about the company’s surrounding its impending first-quarter 2025 financial results, which is slated to release on April 30 before the opening bell. 

This company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $1.15 billion, up 4.4% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Bausch + Lomb, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BLCO going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Bausch + Lomb belongs to the Zacks Medical Services industry. Another stock from the same industry, Charles River Laboratories CRL, closed the last trading session 12.5% higher at $139.07. Over the past month, CRL has returned -25.8%.

For Charles River

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research